MSI-H: a truly agnostic biomarker?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. A meta-analysis with systematic review: Efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer.Frontiers in oncology · 2022
   Pooled it
2. Overview on biomarkers for immune oncology drugs.Exploration of targeted anti-tumor therapy · 2025
   Review
3. The Landscape of Immunotherapy for Retroperitoneal Sarcoma.Current oncology (Toronto, Ont.) · 2023
   Review
4. Predictive value of prognostic nutritional and systemic immune-inflammation indices for patients with microsatellite instability-high metastatic colorectal cancer receiving immunotherapy.Frontiers in nutrition · 2023
   Article
5. Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy.NPJ precision oncology · 2022
   Article
6. An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT.International journal of molecular sciences · 2021
   Review
7. Precision oncology in metastatic colorectal cancer - from biology to medicine.Nature reviews. Clinical oncology · 2021
   Review
8. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer.Journal of personalized medicine · 2021
   Review
9. Artificial Intelligence in Cancer Research and Precision Medicine.Cancer discovery · 2021
   Review
10. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.International journal of cancer · 2020
    Article
11. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.The AAPS journal · 2020
    Review
12. Therapy of Primary Liver Cancer.Innovation (Cambridge (Mass.)) · 2020
    Review

Corrections and comments

• Comment on
  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.2020
• Comment on
  Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as